Authors' recommendations: Cancer is the second most common cause of death in the United States. In 2015, it was estimated that cancer would affect 1,658,370 Americans, causing death in approximately 589,430 cases. The age-adjusted death rate from cancer in the United States from 2008 to 2012 was 171.2 per 100,000 individuals. Of men and women born in the United States today, approximately 40% will be diagnosed with cancer at some stage in their lives. Genetic and genomic testing is of great interest in the evaluation of cancer, as cancer is essentially a disease in which dysfunctional genetic alterations lead to abnormal cell growth and division. Assessment of the particular genetic alterations present in an individual's tumor may provide information of interest in diagnosis, prognosis, or targeted treatment. More comprehensive genomic analysis of a tumor may uncover variants or alterations not identified by established biomarker testing, such as single biomarker or hotspot variant testing. The focus of this report is to assess the evidence for the use of FoundationOne profiling as a decision aid for physicians, providing them with a list of potentially actionable biomarkers to help guide treatment and improve clinical outcomes in patients with solid tumor cancers.

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=44326

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2014 Winifred S. Hayes, Inc